Under 10% of patients who could benefit from obesity jabs like Wegovy are able to get them, warns the World Health Organization as it issues its inaugural recommendations on the drugs.
Considering in excess of 1,000,000,000 individuals worldwide now classified as obese, it is advocating for increased and just availability to GLP-1 medication.
Based on estimates, in excess of 2,000,000,000 are projected to be obese by 2030 without intervention.
"The latest guidelines recognises that excess weight is a long-term condition that can be treated with holistic and lifelong care," remarked the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and logistical bottlenecks are significant hurdles to universal access to the injections that can help people shift significant body mass, explains the agency.
Weight-Loss Drug Supply Crisis
Even in the current most favorable scenario, the manufacturing of GLP-1 therapies might only reach around 100 million people – under 10% of those who need them, per the WHO.
The recommendation encourages governments and firms to widen availability, via measures such as patent sharing.
A patent on the active ingredient – the main ingredient of a leading brand – is scheduled to end in several nations in 2026.
How Weight-Loss Injections Operate
These medications imitate a natural hormone to delay gastric emptying, curb appetite and increase satiety so people reduce food intake.
People usually begin shedding pounds after several weeks of starting on the weekly injections.
Evidence suggests patients may regain a significant portion within a year of stopping the medication, because their typical hunger come back.
Being carrying excess weight raises your risk for developing diseases, like diabetes, heart disease, stroke, and specific malignancies.
Obesity concerns individuals in countries worldwide and was responsible for over three and a half million deaths worldwide in 2024, per the health agency.
